Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Board Change

9 Nov 2022 07:00

RNS Number : 7543F
NetScientific PLC
09 November 2022
 

For release: 9 November 2022

NetScientific plc

("NetScientific" or "NSCI" or the "Company" or the "Group")

Board Change

London, UK - 9 November 2022: NetScientific Plc (AIM: NSCI), the active international holding company, which invests in, develops, and commercialises life sciences/healthcare, sustainability, and technology companies, today announces that John Clarkson is relinquishing his executive status and becoming Non-Executive Chairman of the Company with immediate effect.

John joined the NetScientific Board in December 2019, was appointed as Non-Executive Chairman in March 2020, and stepped into the role of Executive Chairman in December 2020. During this three year period, the Company has made substantial progress with the turnaround of the business and implementation of its growth strategy to deliver shareholder value, with proactive commercial management, a capital light investment model, trans-Atlantic development, and expansion of the portfolio from 8 to 23 companies.

John has indicated his wish to step down from the NetScientific Board during the first quarter of 2023 and has agreed to remain in the role of Non-Executive Chairman of the Company whilst the Company concludes its search for the appointment of a new Chair. It has also been agreed that John will, until 31 December 2023, provide various consultancy and advisory services to Group companies for an aggregate remuneration that is within his contractual entitlement to payment in lieu of notice.

The Nomination Committee has initiated a search for a new Chair and an announcement will be made in due course.

In the meantime, the Board thanks John for his commitment and support in his capacity as Executive Chairman and looks forward to continuing to work with him in his new role.

The person responsible for arranging the release of this announcement on behalf of the Company is Ilian Iliev, Chief Executive of the Company.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

For more information, please contact:

 

NetScientific

Ilian Iliev, CEO Via Belvedere Communications

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel / Enzo Aliaj +44 (0)20 7220 1666

 

Belvedere Communications

John West / Llew Angus +44 (0) 203 008 6867

Email: nsci@belvederepr.com

 

About NetScientific

NetScientific Plc ("NSCI") is an active holding Company that proactively invests in a global portfolio of companies across the healthcare, life science, ESG, and deep technology sectors.

NetScientific delivers shareholder returns through a proactive and hands-on management approach to its portfolio companies; identifying, investing in, and helping to build game-changing companies. The Group targets value inflection points and the release of value through partial or full exits from trade sales, public listings, or equity sales. The Company has a strong Trans-Atlantic and growing international presence, providing attractive expansion prospects.

The Company differentiates itself by employing a capital-light investment approach, making use of its wholly owned subsidiary, EMV Capital's network of private, corporate, and institutional investors. By syndicating investment and making minimal use of its balance sheet, the Company is able to secure direct stakes, as well as carried interest stakes, in its portfolio. This ultimately creates a structure that can support a large portfolio with a limited balance sheet.

NetScientific is headquartered in London, United Kingdom, and was admitted to trading on AIM, a market operated by the London Stock Exchange, in 2013.

www.netscientific.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABPBTTMTBMTLT
Date   Source Headline
24th May 20177:00 amRNSVortex Initiates Clinical Research Studies
10th May 20177:00 amRNSProAxsis announces additional IP
5th May 20177:00 amRNSProAxsis Presents New Data at Major US Conference
24th Apr 20177:00 amRNSBTG purchases Wanda's shares in Oncoverse
3rd Apr 20177:00 amRNSFull Year Results for the year ended 31 Dec 2016
31st Mar 20177:00 amRNSVortex Biosciences Announces Publications
27th Mar 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSVortex Biosciences Launches VTX-1 Liquid Biopsy
15th Feb 20177:00 amRNSVortex Biosciences' CSO Wins SLAS Innovation Award
9th Feb 20177:00 amRNSVortex Biosciences' CSO Finalist for SLAS Award
30th Jan 20177:00 amRNSGrant of Options to Directors
20th Dec 20167:00 amRNSNew CEO appointed to Wanda
16th Dec 20167:00 amRNSExecuted Warrants
18th Nov 20167:00 amRNSNetscientific: Vortex Biosciences Analysis Data
3rd Nov 20164:34 pmRNSVortex Gains CE Mark and FDA Class 1 Registration
26th Oct 201612:30 pmRNSVortex Biosciences Appoints Non-Executive Director
30th Sep 20167:00 amRNSProAxsis Gains CE Mark for its Respiratory Test
27th Sep 20167:00 amRNSNetScientific Interim Results
23rd Sep 20167:00 amRNSWanda Technology Selected by 24Hr HomeCare
12th Sep 20167:00 amRNSGlycotest strengthens IP portfolio
8th Sep 20167:00 amRNSWanda Appoints Digital Health Non-Exec Director
6th Sep 20167:00 amRNSNotice of Interim Results
19th Aug 20167:00 amRNSWanda Launches First Consumer App
18th Aug 20167:06 amRNSVortex Biosciences Appoints Experts to New SAB
3rd Aug 20167:00 amRNSVortex Licenses Patents From Harvard University
28th Jul 20167:00 amRNSChange of Adviser
27th Jul 20167:00 amRNSWanda Appoints Medical Director
22nd Jul 20167:00 amRNSA to Z Home Health Care selects Wanda technologies
27th Jun 20167:00 amRNSGrant of Options to Director
15th Jun 20162:13 pmRNSResult of AGM
14th Jun 20167:00 amRNSVortex Biosciences appoints Chairman of SAB
14th Jun 20167:00 amRNSNetScientific hosts Capital Markets Day
10th Jun 20167:30 amRNSConfirmed Start Date for Ian Postlethwaite as CFO
7th Jun 20167:00 amRNSPortfolio PDS Biotechnology presents at BIO 2016
23rd May 20169:00 amRNSNotice of AGM
18th Apr 20167:00 amRNSNetScientific's Vortex presents data at AACR
13th Apr 20167:00 amRNSPDS Biotechnology Reports Positive Phase 1 Results
7th Apr 20167:00 amRNSAnnual Financial Report
5th Apr 20167:00 amRNSNetscientific Appoints Ian Postlethwaite as CFO
30th Mar 20167:00 amRNSProAxsis Forms Scientific Advisory Board
24th Mar 20167:00 amRNSNotice of Results
16th Mar 20167:00 amRNSWanda Forms Scientific Advisory Board
7th Mar 20162:00 pmRNSAdoption of reduced disclosure framework
1st Mar 20161:00 pmRNSVortex co-founder receives US Presidential award
29th Feb 20167:00 amRNSWanda and Dignity Health launch OncoVerse platform
17th Feb 20167:00 amRNSNetScientific appoints Prof. Stephen Smith as NED
9th Feb 201611:05 amRNSPDS Biotechnology partners with NCI
8th Feb 20163:14 pmRNSGrant of Options to Director
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 201611:09 amRNSPDS Biotechnology adds drug development executives

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.